Abstract
Diabetes causes various macrovascular and microvascular alterations often culminating in major clinical complications, first of all is stroke, that, until today, lacks effective therapeutic intervention. N‐Palmitoylethanolamine‐oxazoline (PEA‐OXA) possesses anti‐inflammatory and potent neuroprotective effects. Although, recent studies have explained the neuroprotective properties of PEA‐OXA, nothing is known about its effects in treating cerebral ischemia. The aim of this study is to explore the mechanism and the effect of PEA‐OXA against cerebral ischemic/reperfusion injury using the transient middle cerebral artery occlusion (MCAo) model in diabetic rats. Neurological severity score and infarct volumes were carried out to assess the neuroprotective effects of PEA‐OXA. Moreover we observed PEA‐OXA‐mediated improvements in tissues histology shown by reduction of lesion size and improvement in apoptosis level (assessed by Caspases, Bax and Bcl‐2 modulation and TUNEL assay) further support the efficacy of PEA‐OXA therapy. We also found that PEA‐OXA treatment was able to reduce mast cell degranulation and to block infiltration of astrocytes and microglia and reduced MCAo‐induced expression of cytokines, nitrotyrosine, MDA, VEGF and TGF‐b, as well as was competent to re‐establish growth factors such as BDNF, GDNF and NGF. PEA‐OXA also inhibited the MCAo‐mediated increased expression of NAAA and NF‐κB and degradation of IκB‐α. PEA‐OXA treated injured animals also improved neurobehavioral functions as evaluated by water maze test. Based on these findings, we propose that PEA‐OXA would be useful in decreasing the risk of impairment or improving function in ischemia‐reperfusion brain injury‐related disorders.Support or Funding Informationno fundingThis abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
